CANBRIDGE PHARM.DL-00001 (F:MF1) — Market Cap & Net Worth
Market Cap & Net Worth: CANBRIDGE PHARM.DL-00001 (MF1)
CANBRIDGE PHARM.DL-00001 (F:MF1) has a market capitalization of $99.79 Million (€85.36 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #19297 globally and #1769 in its home market, demonstrating a -12.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CANBRIDGE PHARM.DL-00001's stock price €0.17 by its total outstanding shares 511120234 (511.12 Million). Also see MF1 asset base for a full breakdown of the balance sheet.
CANBRIDGE PHARM.DL-00001 Market Cap History: 2022 to 2026
CANBRIDGE PHARM.DL-00001's market capitalization history from 2022 to 2026. Data shows change from $152.97 Million to $99.79 Million (-17.48% CAGR). Also see CANBRIDGE PHARM.DL-00001 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
CANBRIDGE PHARM.DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CANBRIDGE PHARM.DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MF1 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.30x
CANBRIDGE PHARM.DL-00001's market cap is 2.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.74x
CANBRIDGE PHARM.DL-00001's market cap is 7.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $152.97 Million | $78.97 Million | -$483.48 Million | 1.94x | N/A |
| 2023 | $65.13 Million | $102.87 Million | -$378.84 Million | 0.63x | N/A |
| 2024 | $7.77 Million | $85.10 Million | -$442.62 Million | 0.09x | N/A |
| 2025 | $114.73 Million | $49.98 Million | $14.82 Million | 2.30x | 7.74x |
Competitor Companies of MF1 by Market Capitalization
Companies near CANBRIDGE PHARM.DL-00001 in the global market cap rankings as of September 20, 2026. Review CANBRIDGE PHARM.DL-00001 tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CANBRIDGE PHARM.DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
CANBRIDGE PHARM.DL-00001 Historical Marketcap From 2022 to 2026
Between 2022 and today, CANBRIDGE PHARM.DL-00001's market cap moved from $152.97 Million to $ 99.79 Million, with a yearly change of -17.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €99.79 Million | -13.02% |
| 2025 | €114.73 Million | +1376.92% |
| 2024 | €7.77 Million | -88.07% |
| 2023 | €65.13 Million | -57.42% |
| 2022 | €152.97 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of CANBRIDGE PHARM.DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $99.79 Million USD |
| MoneyControl | $99.79 Million USD |
| MarketWatch | $99.79 Million USD |
| marketcap.company | $99.79 Million USD |
| Reuters | $99.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more